Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma.
Verhoeff SR, Oosting SF, Elias SG, van Es SC, Gerritse SL, Angus L, Heskamp S, Desar IME, Menke-van der Houven van Oordt CW, van der Veldt AAM, Arens AIJ, Brouwers AH, Eisses B, Mulders PFA, Hoekstra OS, Zwezerijnen GJC, van der Graaf WTA, Aarntzen EHJG, Oyen WJG, van Herpen CML. Verhoeff SR, et al. Among authors: gerritse sl. Clin Cancer Res. 2023 Feb 1;29(3):592-601. doi: 10.1158/1078-0432.CCR-22-0921. Clin Cancer Res. 2023. PMID: 36394882 Free PMC article.
Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, der Houven van Oordt CWM. van Helden EJ, et al. Among authors: gerritse sl. Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2481. doi: 10.1007/s00259-020-04908-6. Eur J Nucl Med Mol Imaging. 2020. PMID: 32535653 Free PMC article.
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
van Helden EJ, Elias SG, Gerritse SL, van Es SC, Boon E, Huisman MC, van Grieken NCT, Dekker H, van Dongen GAMS, Vugts DJ, Boellaard R, van Herpen CML, de Vries EGE, Oyen WJG, Brouwers AH, Verheul HMW, Hoekstra OS, Menke-van der Houven van Oordt CW. van Helden EJ, et al. Among authors: gerritse sl. Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):849-859. doi: 10.1007/s00259-019-04555-6. Epub 2019 Nov 9. Eur J Nucl Med Mol Imaging. 2020. PMID: 31705176 Free PMC article.
Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.
Rovithi M, Gerritse SL, Honeywell RJ, Ten Tije AJ, Ruijter R, Peters GJ, Voortman J, Labots M, Verheul HMW. Rovithi M, et al. Among authors: gerritse sl. J Clin Oncol. 2019 Feb 10;37(5):411-418. doi: 10.1200/JCO.18.00725. Epub 2018 Dec 26. J Clin Oncol. 2019. PMID: 30586316 Free PMC article. Clinical Trial.